You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Validation of a Novel Treatment for Glioblastoma

    SBC: CURTANA PHARMACEUTICALS, INC.            Topic: NCI

    ? DESCRIPTION (provided by applicant): The goal of this application is to study in vivo efficacy of CT102, a newly discovered inhibitor of the OLIG2 transcription factor in animal models of glioblastoma (GBM), a highly underserved area of pharmacotherapy. In this proposal, the experienced drug discovery group at Curtana Pharmaceuticals Inc. will conduct a pre-clinical evaluation of selectivity ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Urocortin-2 Gene Transfer for CHF: a Paracrine Approach Using Intravenous AAV8

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Gene transfer for the treatment of cardiovascular diseases is bedeviled by inability to obtain, safely and easily, sufficient cardiac transgene expression. Current methods of gene transfer for heart disease include intramuscular injection into heart muscle or intracoronary delivery, approaches that are cumbersome to apply. Consequently, we have considered the u ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Targeting of Myc-Max dimerization for the treatment of cancer

    SBC: SORRENTO THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Myc is a key transcriptional regulator due to its critical role in many fundamental cellular processes, such as cell cycle progression and cell growth. Therefore, dysregulation of Myc expression can lead to disease, including cancer. Myc is overexpressed in many human tumors, and it is estimated that 1 in 7 cancer deaths in the United States are resultant of hi ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. RNA Detection as an Improved Diagnostic Assay for Human Leptospirosis

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Leptospirosis a zoonotic disease is an important public health problem worldwide It is caused by spirochete bacteria belonging to nine species and more than serovars of the genus Leptospira In the US there is increasing awareness of the importance of leptospirosis as the cause of disease among inner city populations military personnel and individuals ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Removal of Amyloid-beta Peptides from the Alzheimer's Brain

    SBC: WE BIOSCIENCES, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): As the Alzheimer's disease (AD) population is growing rapidly, currently there are no cure treatments. The goal of this resubmitted STTR proposal is to conduct a preclinical study with pramlintide to prove a potential treatment for AD. We have revised the proposal significantly according to the reviewers' comments. Pramlintide is an FDA approved drug ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Recyclable Magnetic Co/C Hybrid ROMP Reagents, Scavengers and Ligands

    SBC: MATERIA, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): This Fast Track Small Business Technology Transfer study between Materia, Inc. in Pasadena, CA and the University of Kansas intends to build upon successes of our current Phase II Fast Track STTR grant (1R42GM097896-03)which ends on March 30, 2014. Preliminary results serve as a solid foundation for this Fast Track submission entitled Development of Recyclable ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens

    SBC: SILVER LAKE RESEARCH CORPORATION            Topic: NIAID

    DESCRIPTION provided by applicant Bacterial resistance to lactam antibiotics is threatening to limit the effectiveness of this most used class of antibiotics A major contributin factor to this problem is the lack of rapid testing methods for medical practitioners to identify lactam resistant pathogens before prescribing specific antibiotics For urinary tract infections UTIs the most c ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. RAP as a therapeutic for regeneration of the optic nerve after insult

    SBC: Novoron Bioscience Inc.            Topic: N

    DESCRIPTION provided by applicant Like all neurons of the central nervous system CNS retinal ganglion cells fail to regenerate and often die after damage to the optic nerve such as occurs in optic nerve stroke or other optic neuropathies Loss of axonal connectivity and neuronal death that occurs after damage to the optic nerve results in vision loss While therapeutics targeting secondary ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. RAP as a therapeutic compound for neuronal regeneration after spinal cord injury

    SBC: Novoron Bioscience Inc.            Topic: 101

    DESCRIPTION provided by applicant RAP as a therapeutic compound for neuronal regeneration after spinal cord injury Novoron Bioscience Inc RESEARCH andamp RELATED Other Project Information Project Summary There are an estimated to new cases of spinal cord injury SCI each year and million people in the United States are paralyzed in some form due to SCI Currently ther ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Preclinical Efficacy of Silicon-based Dual Energy CT Contrast Material

    SBC: NEXTRAST, INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Our long term goal is to revolutionize the safety and effectiveness of computed tomography (CT) imaging for millions of Americans across a broad range of gastrointestinal disease. Bowel and intravenous contrast materials improve the CT imaging of abdominal disease. Unfortunately, none of the current clinical contrast materials are visibly different from the oth ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government